Citation Impact
Citing Papers
RAS Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant
2010
A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia
2018 StandoutNobel
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes
2012
Cancer and Altered Metabolism: Potential Importance of Hypoxia-Inducible Factor and 2-Oxoglutarate-Dependent Dioxygenases
2011 StandoutNobel
A critical assessment of the “sterile womb” and “in utero colonization” hypotheses: implications for research on the pioneer infant microbiome
2017 Standout
Hallmarks of Cancer: The Next Generation
2011 Standout
Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples
2010
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
2009
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
2009 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Advances in metal-induced oxidative stress and human disease
2011 Standout
Regulation of chromatin by histone modifications
2011 Standout
Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes
2012
Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS
2011
ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia
2010
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
The changing landscape of atherosclerosis
2021 StandoutNature
Estimating the prevalence of myelodysplastic syndromes in patients with unexplained cytopenias: A retrospective study of 322 bone marrows
2009
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
2018 StandoutNobel
Constitutive interaction of the P2Y2 receptor with the hematopoietic cell-specific G protein Gα16 and evidence for receptor oligomers
2004
Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions
2009
Key roles of histone methyltransferase and demethylase in leukemogenesis
2010
IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis
2010
Isothermal nucleic acid amplification technologies for point-of-care diagnostics: a critical review
2012
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes
2010
Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes
2015 StandoutNobel
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
2013 StandoutNobel
Dysplasia Has A Differential Diagnosis: Distinguishing Genuine Myelodysplastic Syndromes (MDS) From Mimics, Imitators, Copycats and Impostors
2012
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
2008 StandoutNature
Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes
2003
TET enzymes, TDG and the dynamics of DNA demethylation
2013 StandoutNature
Acquired mutations in TET2 are common in myelodysplastic syndromes
2009
Therapy-related myeloid neoplasms following treatment with radioiodine
2011
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
2011 Standout
A Lymphoid Tissue-Specific Receptor, EDG6, with Potential Immune Modulatory Functions Mediated by Extracellular Lysophospholipids
1999
Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: The diagnostic interface
2007
Somatic point mutations in RUNX1/CBFA2/AML1 are common in high‐risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia
2004
Applications of machine learning in drug discovery and development
2019 Standout
Therapy with azanucleosides for myelodysplastic syndromes
2010
Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys
2008
Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy
2009
A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification
2007
A decade of exploring the cancer epigenome — biological and translational implications
2011 Standout
Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells
2013
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
2005 Standout
Clinical and genetic predictors of prognosis in myelodysplastic syndromes
2014
The Polycomb complex PRC2 and its mark in life
2011 StandoutNature
Activity and DNA contamination of commercial polymerase chain reaction reagents for the universal 16S rDNA real-time polymerase chain reaction detection of bacterial pathogens in blood
2008
Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily
2009
Cell signalling diversity of the Gqα family of heterotrimeric G proteins
2005
CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine
2007
Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification
2009
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
2003 Standout
Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes
2011
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy
2014
Myelodysplastic Syndromes Clinical Practice Guidelines in Oncology
2006
Recent developments in myelodysplastic syndromes
2014
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes
2005
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals
2003
The emerging role of immune checkpoint based approaches in AML and MDS
2017 StandoutNobel
Diagnosing COVID-19: The Disease and Tools for Detection
2020 Standout
DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes
2009
High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival
2008
Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes
2013
The molecular classification of multiple myeloma
2006
Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists
2002 StandoutScience
Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum
2011 StandoutScience
The First Microbial Colonizers of the Human Gut: Composition, Activities, and Health Implications of the Infant Gut Microbiota
2017 Standout
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
2015 Standout
Receptors for Purines and Pyrimidines
2012 Standout
Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes
2007
Guidelines for the management of thyroid cancer
2014 Standout
Multiple Myeloma
2011 Standout
Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure
2016
The World Health Organization (WHO) classification of the myeloid neoplasms
2002 Standout
Flow cytometric immunophenotyping for hematologic neoplasms
2008
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia
2014
World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes
2007
Works of Michael Pfeilstöcker being referenced
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference
2007
Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes
2009
Dysplastic versus proliferative CMML – a retrospective analysis of 91 patients from a single institution
2001
Evaluation of antileukaemic effects of rapamycin in patients with imatinib‐resistant chronic myeloid leukaemia
2007
Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma
2004
Preanalytic removal of human DNA eliminates false signals in general 16S rDNA PCR monitoring of bacterial pathogens in blood
2008
Time changes in predictive power of established and recently proposed clinical, cytogenetical and comorbidity scores for Myelodysplastic Syndromes
2011
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)
2005
Cross‐validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics
1999
Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group
2009
Proposed score for survival of patients with myelodysplastic syndromes
2013
Expression of G alpha 16, a G-protein alpha subunit specific for hematopoiesis in acute leukemia.
1996
Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System
2011
Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution
2001
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients
2007